Clinical Trials Logo

Clinical Trial Summary

0116-ASG REMETY is a multicenter, open-label, non-randomized, dose-escalation Phase I study evaluating the safety and anti-tumor activity of TAS-102 administered in combination with Regorafenib in patients with metastatic colorectal cancer.


Clinical Trial Description

The primary objective is to determine safety, feasibility and the recommended phase II dose (RP2D) of a combination treatment consisting of TAS-102 and Regorafenib in subjects with mCRC who have progressed after standard therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03305913
Study type Interventional
Source AIO-Studien-gGmbH
Contact
Status Completed
Phase Phase 1
Start date July 31, 2017
Completion date April 26, 2019